Tirzepatide is a double glucagon hormone receptor agonist (GLP-1 and GIP receptors), making it more effective for body fat mass reduction than its predecessor Semaglutide (Ozempic) by targeting further receptors.

The peptide incorporates a C20 fatty diacid moiety via a γGlu-(AEEA)₂ linker enabling reversible albumin binding and an extended pharmacokinetic profile compatible with once-weekly dosing.

It is the first dual GIP / GLP-1 receptor agonist approved by the FDA (Mounjaro® 2022, Zepbound® 2023) and serves as the reference compound for the broader class of multi-incretin analogs.

Benefits (Research Focus)

• Dual receptor agonism — studied for simultaneous activation of GIP and GLP-1 receptors with imbalanced biased agonism
• Glycemic control research — investigated for fasting glucose, HbA1c, and insulin sensitivity parameters in T2D models
• Body composition — examined for fat-mass and lean-mass partitioning in obesity models
• Gastric emptying — explored for delayed gastric transit and downstream satiety endpoints
• Long-acting profile — C20 fatty diacid albumin-binding chemistry for extended half-life (~5 days)

⚠️ Disclaimer

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment.

****** ON SALE DUE TO FACTORY ERROR ******

****** ORDERED AS RETATRUTIDE – RECEIVED AND TESTED AS TIRZEPATIDE ******

****** 99.62% PURITY TIRZEPATIDE – SEE NOTES ON COA REPORT ******